IAPO launched the Patient-Centred Healthcare Indicators Review
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 1
Abstract
In October 2012, the International Alliance of Patients’ Organizations (IAPO) launched its final Patient-Centred Healthcare Indicators Review and accompanying consultation report [1]. The review forms the initial stage of a wider project being undertaken by IAPO to develop a set of process and outcome indicators of patient-centredness. Indicators of patient-centredness relevant to activities, organizations and countries can support the development and implementation of patient-centred policies and be applied by relevant stakeholders to measure the extent and quality of their work towards being patient-centred. The review identifies and assesses current initiatives, which aim to measure the patient-centredness of organizations, countries, activities and any other relevant stakeholders involved in health care. It includes examples from World Health Organization, national health systems, hospitals and others.
Authors and Affiliations
Yasemin Dil
Keywords
Related Articles
- EP ID EP355127
- DOI 10.5639/gabij.2013.0201.005
- Views 129
- Downloads 0
Suggested evaluation of biological drugs role for WHO – Editor’s response
The Editor-in-Chief expresses his concerns about the proposal of a WHO run system to approve copy biologicals in the Milani and Gaspani paper [1].
Generic medicine pricing: on track in Europe?
There are many variables responsible for the pricing of generic medicines in Europe. This editorial looks at the many policy initiatives currently being undertaken.
European payer initiatives to reduce prescribing costs through use of generics
Introduction: Pharmaceutical expenditure is increasingly scrutinised by payers of health care in view of its rapid growth resulting in a variety of reforms to help moderate future growth. This includes measures across Eu...
Steps to ensure adequate supply of biological medicines: considerations for the healthcare provider
Introduction: When drug shortages occur, healthcare providers (HCPs) often must ration drugs, cancel or delay treatments, or utilize alternative drugs that may be less efficacious and/or are associated with increased ris...
Italy’s final position paper on biosimilars and new price and reimbursement pathway
The AIFA’s position paper recognizes the relevance of biosimilars to ensure the sustainability of drug expenditure but the new price and reimbursement procedure may not favour their prompt market access.